Difference between revisions of "BRAF mutation"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''BRAF mutation''' is a common genetic change in [[cancer]]. | '''BRAF mutation''' is a common genetic change in [[cancer]]. The most common BRAF mutation is the so-called [[BRAF V600E mutation]]. | ||
==General== | ==General== | ||
| Line 11: | Line 11: | ||
*BRAF mutations in ~45-50% of papillary thyroid carcinoma. | *BRAF mutations in ~45-50% of papillary thyroid carcinoma. | ||
*BRAF mutations in ~3% of [[lung adenocarcinoma]]s. | *BRAF mutations in ~3% of [[lung adenocarcinoma]]s. | ||
==See also== | |||
*[[BRAF V600E mutation]]. | |||
*[[KRAS mutation]]. | |||
==References== | ==References== | ||
Revision as of 18:17, 23 January 2019
BRAF mutation is a common genetic change in cancer. The most common BRAF mutation is the so-called BRAF V600E mutation.
General
- Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.[1]
Prevalence
BRAF mutations by tumour type:[1]
- BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
- BRAF mutations in ~ 10% of colorectal tumours.
- Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
- BRAF mutations in ~45-50% of papillary thyroid carcinoma.
- BRAF mutations in ~3% of lung adenocarcinomas.